In-silico Prediction of the Beta-carboline Alkaloids Harmine and Harmaline as Potent Drug Candidates for the Treatment of Parkinson’s disease

(E-pub Ahead of Print)

Author(s): Rumpa Banerjee, Mukesh Kumar, Isha Gaurav*, Sudha Thakur, Abhimanyu Thakur, Kunal Singh, Sanchari Karak, Rajeswar Das, Mohit Chhabra

Journal Name: Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Formerly Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents

Become EABM
Become Reviewer
Call for Editor


Background: Parkinson’s disease (PD) is a progressive neurodegenerative disease manifested by core symptoms of loss of motor control and postural instability. Loss of dopaminergic neurons is the cause of PD, thus enhancing dopamine level by pharmacological treatment is one of the key treatment strategies for PD. However, limitations of current treatment strategies open the possibility of novel drug candidates for the treatment of PD.

Objective: To investigate the anti-PD potential of Harmine and Harmaline. We aim to evaluate the therapeutic potential of Harmine and Harmaline by in-silico approaches; molecular docking, pharmacokinetic and Prediction of Activity Spectra for Substances (PASS) analysis were used for evaluating the therapeutic potential of Harmine and Harmaline and standard drug levodopa (L-DOPA).

Methods: Auto dock vina was used for molecular docking of all three compounds against D2- and D3- dopamine receptors. The pharmacokinetics (PKs) and toxicity profile were predicted by pkCSM and the pharmacological activity was predicted by PASS analysis.

Results: Molecular docking showed a higher binding affinity of Harmine and Harmaline as compared to L-DOPA, and these results were supported by in-silico pharmacokinetic and toxicity profiling. Moreover, PASS analysis showed anti-PD activi-ty of Harmine and Harmaline.

Conclusion: Harmine and Harmaline exhibit higher binding affinity towards D2- and D3- dopamine receptors compared to L-DOPA, and PKs and toxicity profile support their potential as drug candidates for PD therapy.

Keywords: Anti-Parkinson’s drug, neurodegenerative disease, neuroscience, pharmacology, molecular docking

Rights & PermissionsPrintExport Cite as

Article Details

Published on: 11 November, 2020
(E-pub Ahead of Print)
DOI: 10.2174/1871523019999201111192344
Price: $95

Article Metrics

PDF: 137